-
Sector Analysis
NewDenmark Beverages Consumption Trends and Forecasts Tracker, Q4 2023
Denmark Beverages Market Overview The Denmark beverages market size was 874.2 million liters (ML) in Q4 2023. The Denmark beverages market research report offers comprehensive consumption volume data across several beverage categories for Q4 2023. Furthermore, the report precisely lists new product launches and highlights the latest beverage industry performance and developments every quarter. The Denmark beverages market outlook also identifies drivers influencing the segmental growth. For instance, packaged water registered an annual volume decline due to low purchasing power...
-
Analyst Opinions
NewTop Trends in Foodservice – Industry Insights
Top Trends in Foodservice Report Overview The foodservice industry has rebounded from the pandemic and has drastically changed consumer behaviour vis-Ã -vis, placing orders, payment options, food choices, and consumption patterns. Asia remains the largest foodservice market globally, with the second-highest transaction growth because of the integration of technology in foodservice operations. This is making it easier and more efficient to order food, access a wider range of choices, and have food delivered from a digital device. The trends in the...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Naratuximab Emtansine in Mantle Cell Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Naratuximab Emtansine in Mantle Cell Lymphoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Naratuximab Emtansine in Mantle Cell Lymphoma Drug Details: Naratuximab emtansine...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Naratuximab Emtansine in Follicular Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Naratuximab Emtansine in Follicular Lymphoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Naratuximab Emtansine in Follicular Lymphoma Drug Details: Naratuximab emtansine is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – TPIV-110 in Ductal Carcinoma In Situ
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - TPIV-110 in Ductal Carcinoma In Situ report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. TPIV-110 in Ductal Carcinoma In Situ Drug Details: TPIV-110...
-
Company Insights
NewElevance Health – Digital Transformation Strategies
Elevance Health Digital Transformation Strategies Overview Elevance Health is tapping the power of big data analytics to analyze data and generate insights, improve member engagement, and detect fraudulent claims. AI, big data, cloud, and automation are among the key technologies under focus for the company. The annual ICT spending of Elevance Health was estimated at $3.8 billion in 2023. A major share of this spending is earmarked for acquiring software, network and communications, and hardware from vendors. Elevance Health Inc...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Naratuximab Emtansine in Diffuse Large B-Cell Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Naratuximab Emtansine in Diffuse Large B-Cell Lymphoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Naratuximab Emtansine in Diffuse Large B-Cell Lymphoma Drug Details:...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Naratuximab Emtansine in Extranodal Marginal Zone B-Cell Lymphoma (Mucosa-Associated Lymphoid Tissue or MALT-Lymphoma)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Naratuximab Emtansine in Extranodal Marginal Zone B-Cell Lymphoma (Mucosa-Associated Lymphoid Tissue or MALT-Lymphoma) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Naratuximab Emtansine in...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Anetumab Ravtansine in Metastatic Pancreatic Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Anetumab Ravtansine in Metastatic Pancreatic Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Anetumab Ravtansine in Metastatic Pancreatic Cancer Drug Details: Anetumab ravtansine...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Anetumab Ravtansine in Endometrial Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Anetumab Ravtansine in Endometrial Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Anetumab Ravtansine in Endometrial Cancer Drug Details: Anetumab ravtansine (BAY 94-9343)...